A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies.

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new ...

Patients with EGFR-mutated non-small cell lung cancer treated with osimertinib experienced more cancer therapy-related ...

A new study from Moffitt Cancer Center could help doctors predict how well patients with a specific type of lung cancer will respond to new therapies. The research, published in Clinical Cancer ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

H.C. Wainwright adjusted its outlook on Cullinan Oncology Inc. (NASDAQ:CGEM), raising the price target to $33.00 from the previous $28.00 while maintaining a Buy rating on the company's shares.

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. have announced the successful outcome ...

Cullinan Therapeutics has announced that its lead asset has aced a midstage lung cancer trial—but the biotech is keeping the ...

Patients are significantly more likely to experience treatment-related cardiac events with osimertinib than with other EGFR TKIs, data suggest.